# MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

> **NCT05708924** · PHASE1 · TERMINATED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 1 (actual)

## Conditions studied

- Cancer
- Solid Tumor
- Ovarian Cancer
- Peritoneal Cancer
- Fallopian Tube Cancer

## Interventions

- **DRUG:** FT538
- **BIOLOGICAL:** Enoblituzumab

## Key facts

- **NCT ID:** NCT05708924
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-04-28
- **Primary completion:** 2024-08-06
- **Final completion:** 2024-08-06
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Product withdrawn from clinical development
- **Last updated:** 2025-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05708924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05708924, "MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT05708924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*